It has been established that cancer patients have immunosuppressive substances in their sera that depress cellular immunity. Although plasma exchanges have been attempted to remove these substances and to improve immunity to cancer, little is known about its mechanism from the viewpoint of cytokine pattern. The levels of the cytokines, tumour necrosis factor-α, interleukin 1β, interleukin 6, interferon-γ and interleukin-1 receptor antagonist (IL-1ra) by peripheral blood mononuclear cells (PBMC) were determined simultaneously by the whole-blood assay and the PBMC assay in 20 patients with gastric cancer and in 10 healthy volunteers. In both assays the cytokine levels were lower in patients with cancer compared with healthy controls, with the exception of IL-1ra. In the PBMC assay, the IL-1ra level in cancer patients was significantly higher than that in controls. No statistical correlation between the cytokine levels determined by the two assays was found. We suggest that autologous serum deprivation restored and enhanced IL-1ra production, and normalized the cytokine cascade in immune response, in patients with gastric cancer.
UchidaAHoshinoT: Clinical studies on cell-mediated immunity in patients with malignant disease. I. Effect of immunotherapy with OK-432 on lymphocyte subpopulation and phytomitogen responsiveness in vitro. Cancer1980; 45: 476–483
2.
SatoMGotoSKanekoR: Impaired production of Th1 cytokines and increased frequency of Th2 subsets in PBMC from advanced cancer patients. Anticancer Res1998; 18: 3951–3955
AnaissieEJBodeyGP: Fungal infection in patients with cancer. Pharmacotherapy1990; 10: 164–169
5.
HellstromKEHellstromI: Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens. Adv Immunol1974; 18: 209–277
6.
BaldwinRWPriceMRRobinsRA: Blocking of lymphocyte-mediated cytotoxicity for rat hepatoma cells by tumor-specific antigen-antibody complexes. Nat New Biol1972; 238: 185–187
7.
GorczynskiRMKilburnDGKnightRA: Nonspecific and specific immunosuppression in tumor-bearing mice by soluble immune complexes. Nature1975; 254: 141–143
8.
Suciu-FocaNBudaJMcManusJ: Impaired responsiveness of lymphocytes and serum-inhibitory factors in patients with cancer. Cancer Res1973; 33: 2371–2377
9.
WangBSBadgerAMNimbergRR: Suppression of tumor-specific cell-mediated cytotoxicity by immunoregulatory alpha-globulin and by immunoregulatory alpha-globulin-like peptides from cancer patients. Cancer Res1981; 41: 3244–3252
10.
TamuraKShibataYMatsudaY: Isolation and characterization of an immunosuppressive acidic protein from ascitic fluids of cancer patients. Cancer Res1983; 43: 2889–2896
11.
ShibataYTamuraKIshidaN: Cultured human monocytes, granulocytes and a monoblastoid cell line (THP-1) synthesize and secrete immunosuppressive acidic protein (a type of alpha 1-acid glycoprotein). Microbiol Immunol1984; 28: 99–111
12.
ShibataYTamuraKIshidaN: In vivo analysis of the suppressive effects of immunosuppressive acidic protein, a type of alpha 1-acidic glycoprotein, in connection with its high level in tumor-bearing mice. Cancer Res1983; 43: 2889–2896
13.
KaiharaAIwagakiHGouchiA: Soluble intercellular adhesion molecule-1 and natural killer cell activity in gastric cancer patients. Res Commun Mol Pathol Pharmacol1998; 100: 283–300
14.
IwagakiHHizutaATanakaN: Interleukin-1 receptor antagonists and other markers in colorectal cancer patients. Scand J Gastroenterol1997; 32: 577–581
15.
KirchnerHKleinickeCHDigelW: A whole-blood technique for testing production of human interferon by leukocytes. J Immunol Methods1982; 48: 213–219
DinarelloCA: Interleukin-1 and interleukin-1 antagonism. Blood1991; 77: 1627–1652
18.
EisenbergSPBrewerMTVerderberE: Interleukin-1 receptor antagonist is a member of the interleukin-1 gene family: evolution of a cytokine control mechanism. Proc Natl Acad Sci U S A1991; 88: 5232–5236
19.
GranowitzEVClarkBDMancillaJ: Interleukin-1 receptor antagonist competitively inhibits the binding of interleukin-1 to the type-II interleukin-1 receptor. J Biol Chem1991; 266: 14147–14150
20.
DrippsDJBrandhuberBJThompsonRC: Effect of IL-1ra on IL-1 signal transduction. J Biol Chem1991; 3: 10331–10336
21.
HendersonBThompsonRCHardinghamT: Inhibition of interleukin-1 induced synovitis and articular cartilage proteoglycan loss in the rabbit knee by recombinant human interleukin-1 receptor antagonist. Cytokine1991; 3: 246–249
22.
AlexanderHRDohertyGMVenzonDJ: Recombinant interleukin-1 receptor antagonist (IL-1ra): effective therapy against gram-negative sepsis in rats. Surgery1992; 112: 188–194
23.
CominelliFNastCCDuchiniA: Recombinant interleukin-1 receptor antagonist blocks the proinflammatory activity of endogenous interleukin-1 in rabbit immune colitis. Gastroenterology1992; 103: 65–71
24.
SvensonMNedergaardSHeegaardPM: Differential binding of human interleukin-1 (IL-1) receptor antagonist to natural and recombinant soluble and cellular IL-1 type-1 receptors. Eur J Immunol1995; 25: 2842–2850
25.
IwagakiHHizutaAKohkaH: Circulating levels of soluble CD30 and other markers in colorectal cancer patients. J Med1999; 30: 111–121
26.
DiamondMSStautonDEde FougerollesAR: ICAM-1 (CD54): a counter-receptor for Mac-1 (CD11a/CD18). J Cell Biol1990; 3: 3129–3141
27.
MarlinSDSpringerTS: Intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen-1 (LFA-1). Cell1987; 51: 831–839
28.
MakgobaMWSandersMEGintherGE: ICAM-1 is a ligand for LFA-1-dependent adhesion of B, T and myeloid cells. Nature1988; 331: 86–88
29.
SimmonsDMakgobaMWSeedB: ICAM, an adhesion ligand of LFA-1, is homologous to the neural cell adhesion molecule NCAM. Nature1988; 331: 624–627
30.
WawrykSONovotnyJRWicksIP: The role of the LFA-1/ICAM-1 interaction in human leukocyte homing and adhesion. Immunol Rev1989; 108: 135–161
31.
BarkerJNWNSarmaVMitraRS: Marked synergism between tumor necrosis factor-α and interferon-γ in regulation of keratinocyte-derived adhesion molecules and chemotactic factors. J Clin Invest1990; 85: 605–608
32.
DustinMLSpringerTA: Lymphocyte function-associated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells. J Cell Biol1988; 107: 321–331
33.
KohkaHYoshinoTIwagakiH: Interleukin-18/interferon-γ inducing factor (IL-18/IGIF), a novel cytokine, upregulates ICAM-1 (CD54) expression in KG-1 cells. J Leukoc Biol1998; 64: 519–527
34.
LittleMCGawkrodgerDGNeilSM: Differentiation of human keratinocytes is associated with a progressive loss of interferon-γ-induced intercellular adhesion molecule-1 expression. Br J Dermatol1996; 135: 24–31
35.
RothleinRCzajkowskiMO'NeilMM: Induction of intercellular adhesion molecule-1 on primary and continuous cell lines by proinflammatory cytokines. Regulation by pharmacological agents and neutralizing antibodies. J Immunol1988; 141: 1665–1669
36.
BurtonJGoldmanCKRaoP: Association of intercellular adhesion molecule-1 with the chain high-affinity interleukin-2 receptor. Proc Natl Acad Sci U S A1990; 87: 7329–7333
37.
CimonoGMandalliF: Second primary cancers following Hodgkin's disease: update results of an Italian multicenter study. J Clin Oncol1991; 9: 432–437
38.
EnbladGSundstomCGlimeliusB: Immunohistochemical characteristics of Hodgkin and Reed-Sternberg cells in relation to age and clinical outcome. Histopathology1993; 22: 535–541
39.
GauseAPohlCTschierschA: Clinical significance of soluble CD30 antigen in the sera of patients with untreated Hodgkin's disease. Blood1991; 77: 1983–1988
40.
PfreundshuhMPohlCBerenbeckC: Detection of a soluble form of the CD30 antigen in the sera of patients with lymphoma, adult T-cell leukemia and infectious mononucleosis. Int J Cancer1990; 45: 869–872
41.
SethRRaymondFDMakgobaMW: Circulating ICAM-1 isoforms: diagnostic prospects for inflammatory and immune disorders. Lancet1991; 338: 83–85
WallgrenACFesttinRGidlofC: Efficient killing of chronic B-lymphocytic leukemia cells by superantigen-directed T cells. Blood1993; 82: 1230–1238
44.
WelderCALeeDHJTakeiF: Inhibition of cell adhesion by microspheres coated with recombinant soluble intercellular adhesion molecule-1. J Immunol1993; 150: 2203–2210
45.
PorteuFNathanC: Shedding of tumor necrosis factor receptors by activated human neutrophils. J Exp Med1990; 172: 599–607
46.
LantzMGullbergENilssonE: Characterization in vitro of a human tumor necrosis factor-binding protein: a soluble form of a tumor necrosis factor receptor. J Clin Invest1990; 86: 1396–1402
47.
EngelmannHDAderkaDRubinsteinM: A tumor necrosis factor-binding protein purified to homogenity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem1989; 264: 11947–11980
48.
SpinasJAKellerUBockhausM: Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxinemia. J Clin Invest1992; 90: 533–536
49.
SmithJW: Therapeutic apheresis in the United States: current indications and directions. Therapeutic Apheresis1999; 2: 182–184
50.
TaniTNumaKHanasawaK: Blood purification therapy in cancer treatment. Therapeutic Apherersis1998; 2: 182–184
51.
HiraiKIshikoODeguchiM: Effects of plasmapheresis in a rabbit model of cancer cachexia. Osaka City Med J1998; 44: 1–15
